Pserosis prescription
Search PubMed for psorosis treatment guidelines
Searching PubMed
"psoriasis"[MeSH Terms] AND "treatment guidelines"
Searching the Web
psoriasis treatment guidelines 2024 2025
Here are the key PubMed results and current guidelines for psoriasis treatment:
PubMed Guidelines Found
1. French Guidelines - Systemic Treatments for Moderate-to-Severe Psoriasis (2025 Update)
[PMID: 41469898] - J Eur Acad Dermatol Venereol, Jun 2026
- Most current European update covering systemic therapies for adults with moderate-to-severe plaque psoriasis.
2. Methotrexate in Pediatric Inflammatory Skin Disease (2024)
[PMID: 38342248] - J Am Acad Dermatol, Jun 2024
- Consensus guidelines on methotrexate use in pediatric psoriasis and other inflammatory skin diseases.
3. Generalized Pustular Psoriasis - Expert Recommendations (2024)
[PMID: 38972580] - Actas Dermosifiliogr, Sep 2024
- Management recommendations for the rare GPP subtype.
4. Biologics in Psoriatic Arthritis - Network Meta-Analysis (2025)
[PMID: 39783044] - Expert Rev Pharmacoecon Outcomes Res, Apr 2025
- Cost-effectiveness and comparative efficacy of biologics for psoriatic arthritis.
Current Treatment Landscape (2024-2026)
Mild Psoriasis (Topicals)
| Agent | Class | Notes |
|---|---|---|
| Betamethasone / clobetasol | Topical corticosteroid | First-line |
| Calcipotriol (vitamin D analog) | Topical | Used alone or in combo |
| Roflumilast 0.3% (Zoryve) | Topical PDE4 inhibitor | Approved ages 6+; propylene glycol-free |
| Tazarotene | Topical retinoid | Adjunct |
Moderate-to-Severe Psoriasis (Systemics)
| Agent | Class | Notes |
|---|---|---|
| Methotrexate | Conventional DMARD | Still first-line in many countries |
| Acitretin | Retinoid | Pustular/erythrodermic psoriasis |
| Cyclosporine | Calcineurin inhibitor | Short-term; renal monitoring needed |
| Apremilast (Otezla) | Oral PDE4 inhibitor | Now indicated for all psoriasis types, mild-severe; ages 6+ |
| Deucravacitinib (Sotyktu) | Oral TYK2 inhibitor | 4-year safety data published 2025 (POETYK PSO trials) |
| Zasocitinib (TAK-279) | Next-gen TYK2 inhibitor | Phase 3 positive results Dec 2025; pending approval |
Biologics
| Drug | Target | Evidence |
|---|---|---|
| Adalimumab, Etanercept, Infliximab | TNF-alpha | Established; now less preferred |
| Secukinumab, Ixekizumab, Bimekizumab | IL-17 | High PASI 90/100 rates |
| Guselkumab, Risankizumab, Tildrakizumab | IL-23 (p19) | Excellent durability |
| Ustekinumab | IL-12/23 (p40) | Now largely superseded |
| Spesolimab | IL-36R | Approved for generalized pustular psoriasis |
Newest Pipeline (2025-2026)
- Icotrokinra - First oral IL-23 receptor antagonist peptide; published NEJM 2025 showing high clearance in scalp and genital psoriasis
- Roflumilast foam - For scalp psoriasis ages 12+
- S3 German/EuroGuiDerm guideline 2025 - comprehensive treatment algorithm now available open-access
Treatment Algorithm Summary
Mild (BSA <10%, DLQI <10)
→ Topical steroids + vitamin D analogs ± roflumilast
Moderate-to-severe (BSA >10% OR DLQI >10 OR special sites)
→ Phototherapy (NB-UVB) OR conventional systemics (MTX, cyclosporine)
→ If inadequate: Biologics (IL-17 or IL-23 inhibitors preferred)
→ Oral small molecules (apremilast, deucravacitinib) as alternatives
Special subtypes (GPP, erythrodermic, psoriatic arthritis) require tailored approaches - spesolimab is now the targeted option for GPP.
This is a shared conversation. Sign in to Orris to start your own chat.